AzTrials
AzTrials

Pulmonary EmbolismNCT01112917

VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial

A study testing VenaTech Convertible Vena Cava Filter and Vena Cava Filter Conversion in people with Pulmonary Embolism, run by B. Braun Interventional Systems, Inc at 11 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The investigation is designed to verify that clinical use of the vena cava filter does not raise new questions of safety or effectiveness compared to currently-marketed permanent filters. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pulmonary Embolism
What is being tested?
VenaTech Convertible Vena Cava Filter and Vena Cava Filter Conversion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
149 participants
Where
11 sitesUnited States
Study dates
Dec 2011to Sep 2015
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The subject is 18 years of age or older
  • The subject is at a time-limited risk of pulmonary embolism as judged by the implanting or referring physician
  • In the physician's judgment, the subject requires prevention of pulmonary embolism and placement of a vena cava filter is indicated because anticoagulants are contraindicated, or the subject has experienced failure of anticoagulant therapy in thromboembolic diseases in the past, or the subject requires emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced
  • The subject, or their legal representative, is willing and able to provide informed consent
  • The subject is willing and able to comply with the requirements of the study protocol, including the predefined follow-up visit evaluations
  • The subject's vena cava diameter is ≤ 28 mm as evaluated by contrast venacavography and corrected for magnification

Who cannot join

  • The subject is a female of childbearing potential and known to be, or suspected to be, pregnant (verified with a urine/blood pregnancy test), or unwilling to use an acceptable form of birth control for as long as the device is implanted
  • The subject is severely disabled and his/her life expectancy appears limited according to the investigator's opinion (≤ 6 months)
  • The subject already has an implanted vena cava filter
  • The subject has contrast allergy to both iodinated contrast and non-iodinated contrast materials
  • The subject has a duplicated IVC
  • The subject is bacteremic
Show all 11Show fewer
  • The subject has an active malignancy with associated hypercoagulability or mortality likely preventing the VenaTech Convertible filter from being converted within 6 months of implant
  • The subject would be unavailable for follow-up
  • Filter implantation using the right internal jugular or femoral veins is not possible
  • There is no location available in the infrarenal inferior vena cava for placement of the VenaTech Convertible vena cava filter (assessed using contrast venacavography)
  • The subject is currently participating in another clinical study or has participated in one within the last 30 days or plans to participate in one during the next 6 months

Trial locations and contacts

11 sites in 1 country.

11 sites in 1 country

United States11 sites
  • Abington Memorial Hospital

    Abington, Pennsylvania, 19001

  • Medical University of South Carolina

    Charleston, South Carolina, 29403

  • University of Virginia Health Systems

    Charlottesville, Virginia, 22908

  • Northwestern Memorial Hospital

    Chicago, Illinois, 60611

  • Adventist Health System

    Hinsdale, Illinois, 60521

  • North Shore University Hospital - Manhasset

    Manhasset, New York, 11030

  • Baptist Hospital of Miami

    Miami, Florida, 33176

  • Froedtert Memorial Lutheran Hospital

    Milwaukee, Wisconsin, 53226

  • Weill Cornell Medical College - New York Presbyterian Hospital

    New York, New York, 10021

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania, 15212

  • Beaumont Health System

    Royal Oak, Michigan, 48073

Other trials in United States

About this study

The investigation is designed to verify that clinical use of the vena cava filter does not raise new questions of safety or effectiveness compared to currently-marketed permanent filters.

Read the detailed description

The investigation was designed as a multi-center, prospective, single-arm, historical (literature) controlled clinical study of VenaTech Convertible filter safety and performance in 75 subjects in whom the filter has been implanted, converted, and followed for 6-months. The study could enroll up to 323 patients to ensure 75 converted subjects with 6 months of follow-up data. Converted subjects were followed at 30-days, 3-months, and 6-months post conversion. Subjects that were unable to undergo conversion were followed at 6-months post filter implant (permanent filtration subjects).

Study subjects were to be identified from the pool of candidates with a time-limited risk for pulmonary embolism. Subjects who signed the informed consent were evaluated to determine eligibility for the study based on the inclusion and exclusion criteria. Following completion of baseline procedures including a bilateral Doppler ultrasound of the legs to assess for baseline DVT and contrast venacavography to assess baseline IVC diameter, subjects underwent implantation of the VenaTech Convertible filter.

After device implant, a clinical assessment was completed to determine eligibility for filter conversion. This assessment was done at an interval post-implant and frequency per the investigator's discretion, often with input from the primary care physician. If the clinician determined the subject was no longer at risk for pulmonary embolism, there was no thrombus in or below the filter, and there was no clinically significant deep vein thrombosis (DVT) in the legs, the filter could be converted. After conversion, subjects were followed at 30 days and 3-months by telephone, and at a 6-months post-conversion office visit with imaging (KUB or spot film and Doppler or CT).

If during the conversion clinical assessment(s), the subject remained at risk for pulmonary embolism, additional conversion assessment(s) were completed per the investigator's discretion until the filter was either converted or the subject was determined to require permanent filtration.

At 6-months post-implant, if a study subject's filter had not been converted, no further conversion assessments were to be performed and no attempts were to be made to convert the filter as part of the study. The 6-month post filter implant visit was the final follow-up for nonconverted subjects, which also included imaging (KUB or spot film and Doppler or CT). The study protocol allowed the investigators flexibility as to the best IVC imaging modality based on the condition and anatomy of the subject.

The core laboratory reviewed all screening/baseline, filter implantation, conversion eligibility assessment, conversion, and 6-month follow-up images, with the exception of the ultrasounds. (The core laboratory recommended ultrasound images be evaluated by the expert sonographers at the sites). Additionally, any images taken as a result of a suspected filter-related adverse event or technical complication, with the exception of ultrasounds, were also sent to the core laboratory for review.

Being tested
VenaTech Convertible Vena Cava Filter, Vena Cava Filter Conversion
Medical subject headings
Pulmonary Embolism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VenaTech Convertible Vena Cava FilterDevice

    Prevention of Pulmonary Embolism

  • Vena Cava Filter ConversionProcedure or surgery

    Conversion of VenaTech Convertible filter to open configuration.

Study groups in NCT01112917
Study groupRoleWhat they receive
VenaTech Convertible Vena Cava FilterExperimentalImplantation of the VenaTech Convertible Filter. The filter is pre-loaded in a cartridge (syringe) and provided as a system with introducer accessories and instructions to accommodate delivery and implantation either using the femoral or jugular approach.
Receives: Device: VenaTech Convertible Vena Cava Filter; Procedure: Vena Cava Filter Conversion

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Technical Success

    Technical success is defined as filter conversion without the loss of filter head components in the vasculature or incomplete opening of filtering legs. Further, in the analysis of the data, the sponsor did not count any filters as a 'technically' successful conversion when the operator was unable to snare the filter hook during an attempted conversion.

    Measured: 6-months

Secondary outcomes (1)
  1. Major Device-Related Adverse Events in Converted Subjects

    Measured: 6-months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Apr 2010 (estimated)
  2. Study startDec 2011
  3. Primary completionSep 2015
  4. Study completionSep 2015

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
149 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01112917
Sponsor's protocol ID
CL-104
Status last verified
Jun 2016
First submitted
8 Apr 2010
Last updated
11 Jul 2016
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • Vena Caval Filter Consensus Conference. Recommended reporting standards for vena caval filter placement and patient follow-up. J Vasc Surg. 1999 Sep;30(3):573-9. No abstract available.

    PubMed 10477662
  • Grassi CJ, Swan TL, Cardella JF, Meranze SG, Oglevie SB, Omary RA, Roberts AC, Sacks D, Silverstein MI, Towbin RB, Lewis CA; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for percutaneous permanent inferior vena cava filter placement for the prevention of pulmonary embolism. J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S271-5. No abstract available.

    PubMed 14514832

Questions about this trial

What is this clinical trial studying?

A study testing VenaTech Convertible Vena Cava Filter and Vena Cava Filter Conversion in people with Pulmonary Embolism, run by B. Braun Interventional Systems, Inc at 11 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 11 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 11 Jul 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Technical Success (time frame: 6-months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01112917, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in